AMGN stock forecast, quote, news & analysis

Key Takeaways

• Amgen (AMGN) shares advanced roughly 13.8% over the past 30 days, climbing from a closing level near $385.65 to about $438.95.
• Positive Phase 3 results for dazodalibep in systemic Sjögren's disease and a string of analyst price-target increases fueled the move.
• Over the last quarter, the stock gained approximately 20.5%, building on stronger Q2 earnings and raised full-year 2026 guidance.
• Fast-growing therapies such as Repatha, TEZSPIRE, UPLIZNA, and IMDELLTRA are offsetting biosimilar-driven declines in legacy products Prolia and XGEVA.
• Q3 2026 results are scheduled for November 3, with consensus estimates near $5.77 in earnings per share and $10.05 billion in revenue.

Amgen (AMGN) Company Overview and Market Position

Amgen Inc. is one of the world's largest independent biotechnology companies, headquartered in Thousand Oaks, California. The company develops and commercializes therapies across oncology, cardiovascular disease, inflammation, bone health, neuroscience, and rare disease. Its portfolio includes blockbusters such as Repatha (cholesterol), TEZSPIRE (asthma), Prolia and XGEVA (bone health), Enbrel, Otezla, and the oncology assets IMDELLTRA and BLINCYTO, alongside a growing biosimilar business.

Investors follow AMGN closely because of its scale, diversified revenue base, strong free cash flow, and long track record of dividend increases. The core investment debate centers on whether growth from its newer cardiometabolic, inflammation, and oncology products can outpace the biosimilar erosion now pressuring its older franchises.

Amgen (AMGN) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, AMGN shares rose about 13.8%, moving from a closing price near $385.65 to roughly $438.95. The advance was not a straight line: the stock fell sharply in early September before recovering and then accelerating through mid-October, when it pushed above the $430 level.

The longer three-month picture is even stronger. From a closing level near $364.17, the stock has gained approximately 20.5%, reflecting sustained momentum since Amgen's second-quarter earnings report in early August. The share price has held above both its 50-day and 200-day moving averages during this period, confirming an intact uptrend despite intermittent volatility.

What Drove AMGN Stock Price in the Last 30 Days

The most significant near-term catalyst was Amgen's announcement of positive topline results from the Phase 3 OASIZ 301 trial for dazodalibep in systemic Sjögren's disease, a chronic autoimmune condition with no approved disease-modifying therapies. The trial met its primary endpoint, reducing clinical risk around a potentially important inflammation and immunology asset and prompting renewed analyst attention.

That data triggered a wave of price-target increases. Scotiabank raised its target to $500 from $450, while UBS lifted its target to $470 from $430 and maintained a Buy rating. RBC Capital raised its target to $430 from $400 with an Outperform rating, and Truist moved its target to $380 from $362 while keeping a Hold rating. These revisions reflected improving confidence in Amgen's pipeline and commercial execution heading into third-quarter results.

The move also reflected a rotation back toward large-cap biotech as investors favored companies with visible topline growth and durable cash generation. This offset a modest negative headwind from the FDA's approval of Teva's Degevma, a biosimilar to Amgen's Xgeva.

What Drove AMGN Stock Performance Over the Last Quarter

The quarterly gain was anchored by Amgen's second-quarter report on August 4, when the company posted revenue growth of 10% to $10.1 billion and raised its full-year 2026 outlook. Management lifted the midpoint of its revenue guidance to $38.8 billion from $37.8 billion and increased its adjusted EPS midpoint to $22.90 from $22.40. The stock rose roughly 8% around the release.

Underlying that result was a sharp contrast between Amgen's growth and legacy franchises. Six key growth drivers grew 26% year over year and represented nearly 70% of product sales, led by Repatha (up 37% to $953 million), TEZSPIRE (up 42%), UPLIZNA (up 90%), and IMDELLTRA (up 115%). Meanwhile, Prolia and XGEVA declined about 33% collectively as biosimilar competition accelerated. Additional support came from Repatha primary-prevention cardiovascular data and a positive European regulatory opinion broadening the drug's label.

Trending AI Robots

Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots from a broader universe of hundreds of automated strategies that trade thousands of tickers. Only the top-performing and most relevant bots appear in this section, giving traders a focused view of strategies currently generating strong results. These bots vary widely in approach, holding timeframe, and performance metrics, so investors can evaluate them according to their own risk tolerance and objectives. The page is designed to help traders discover proven algorithmic strategies and monitor how AI systems are navigating live market conditions across equities, including names like Amgen. Visit the Trending AI Robots page to explore the strategies currently gaining traction.

AMGN Stock Forecast Drivers: What Investors Should Watch Next

The next major event is Amgen's Q3 2026 earnings report, scheduled for November 3. Analysts expect earnings per share near $5.77 on revenue of about $10.05 billion, and investors will scrutinize Prolia and XGEVA sales against consensus as biosimilar erosion continues. Guidance updates for the remainder of 2026 will also be in focus, particularly after management signaled that third-quarter operating expenses would rise, including a $100 million upfront business-development payment.

Beyond earnings, watch for full data presentations from the dazodalibep program, progress on late-stage cardiometabolic assets olpasiran and MariTide, and regulatory decisions on biosimilar filings. Competitive dynamics in immunology and oncology, including offerings from AbbVie, Merck, and Bristol Myers Squibb, as well as broader macroeconomic and policy developments, may also influence sentiment.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations